Navigation Links
TGen-NAU professor leads national panel in precedent-setting policy published in Science and Nature
Date:2/1/2012

FLAGSTAFF, Ariz. Feb. 1, 2012 The U.S. National Science Advisory Board for Biosecurity (NSABB) today published a precedent-setting policy statement warning about the "unusually high magnitude" risk from unrestricted publication of avian flu research.

The NSABB is chaired by Dr. Paul Keim, Director of the Pathogen Genomics Division of the Translational Genomics Research Institute (TGen), and a Regents Professor of Biology at Northern Arizona University, and Director of NAU's Center for Microbial Genetics and Genomics.

The NSABB statement concerns recent, though as yet unpublished, research that showed how a strain of deadly avian flu virus could be made that is easily transmitted between mammals, including humans. Currently, the highly pathogenic A/H5N1 avian influenza virus though a serious public health concern since its identification in Asia in 1997 rarely infects people, because it is not easily transmitted among mammals.

The NSABB, which represents dozens of government and academic entities, was asked by the federal government to review the research prior to its publication because of its "dual use," meaning its potential for being used for good or bad purposes.

"A balance must be struck between academic freedom and protecting the greater good of mankind from potential danger," Dr. Keim said, quoting from the policy statement.

The NSABB weighed the benefits of the recent research, which could produce greater preparedness and potentially produce novel strategies leading to disease control, against the threat that details of the research could fall into the wrong hands.

"Because the NSABB found that there was significant potential for harm in fully publishing these results and that the harm exceeded the benefits of publication, we therefore recommended that the work not be fully communicated in an open forum," the policy statement says. "We found the potential risk of public harm to be of unusually high magnitude."

The NSABB statement was published online today by the prestigious scientific journals Science and Nature. It will be published in print by the journals later this month.

"Our concern is that publishing these experiments in detail would provide information to someone or some organization or government that would help them develop similar mammal-adapted influenza A/H5N1 viruses for harmful purposes," the statement says. "A pandemic or the deliberate release of a transmissible highly pathogenic influenza A/H5N1 virus would be an unimaginable catastrophe for which the world is currently inadequately prepared."

The statement notes that science is in a revolutionary period of dramatically expanded technological capabilities, enabling the increased ability to manipulate the genetic material of microbes.

"With this has come unprecedented potential for better control of infectious diseases and significant societal benefit. However, there is also a growing risk that the same science will be deliberately misused and that the consequences could be catastrophic," says the statement, which calls for a "rapid and broad international discussion of dual use research policy concerning A/H5N1 influenza virus with the goal of developing a consensus on the path forward."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. National Science Foundation grants Clemson professors award to develop nanoprobes
2. University professor stresses links between US Navy sonar and whale strandings
3. Minnesota ecology professor wins international award for biodiversity and biofuels research
4. NJIT professors research suggests changes in underwater data communications
5. 2 Alexander von Humboldt professorships go to LMU Munich
6. Top biophysics award to Professor Ray Norton
7. University of Leicester professor adds new perspective to rainforest debate
8. NJIT professor finds engineering technique to identify disease-causing genes
9. Chemistry professor 1 of only 3 at UH to achieve prestigious AAAS status
10. Florida professor creates endowment for insect scientists
11. Dinner, lecture series to honor legacy of distinguished UH professor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... ... January 12, 2017 , ... After ... Lisa Rosendahl’s doctors gave her only a few months to live. Now a ... that has stabilized Rosendahl’s disease and increased both the quantity and quality of ...
(Date:1/12/2017)... and Pune, India , January 12, 2017 ... Toxicity Testing Market by Type and End Users - Global Opportunity Analysis and Industry ... million by 2022 from $2,921 million in 2015, growing at a CAGR of 15.07% ... ... Allied Market Research Logo ...
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
Breaking Biology Technology: